Join the Diabetic Macular Edema group to help and get support from people like you.
Diabetic Macular Edema News
Related terms: DME
FDA Approves Eylea HD (aflibercept) Injection 8 mg for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea HD (aflibercept)...
Dexamethasone Best for Persistent, Recurrent Uveitic Macular Edema
THURSDAY, June 22, 2023 – For patients with minimally active or inactive uveitis and persistent or recurrent uveitic macular edema (ME), dexamethasone is significantly better for treatment than...
AI Can Estimate Best-Corrected Visual Acuity With Diabetic Macular Edema
MONDAY, June 12, 2023 – Artificial intelligence (AI)-determined best-corrected visual acuity (BCVA) from remotely obtained fundus photographs is feasible for evaluating diabetic macular edema (DME),...
Automated Diabetic Macular Ischemia Algorithm Predicts Retinopathy Progression
WEDNESDAY, May 31, 2023 – For patients with diabetes, an automated binary diabetic macular ischemia (DMI) algorithm using optical coherence tomography angiography (OCTA) images predicts diabetic...
FDA Approves Cimerli (ranibizumab-eqrn), an Interchangeable Biosimilar to Lucentis
REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has...
Novartis Announces FDA Approval of Beovu for the Treatment of Diabetic Macular Edema
Approval is based on year one data from the Phase III KESTREL and KITE clinical trials investigating Beovu (brolucizumab-dbll) 6 mg versus aflibercept 2 mg in DME patients1,2 In KESTREL and KITE,...
FDA Approves Vabysmo (faricimab-svoa) for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration and Diabetic Macular Edema
South San Francisco, CA – January 28, 2022 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA – March 21, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the...
FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema
March 25, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema. ...
FDA Approves Revised Indication for Ozurdex for the Treatment of Diabetic Macular Edema
IRVINE, Calif.-September 29, 2014 - Allergan, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Ozurdex (dexamethasone intravitreal implant) 0.7 mg, a...
FDA Approves Iluvien for Diabetic Macular Edema
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug...
Eylea (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema
TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept)...
Ask a question
To post your own question to this support group, sign in or create an account.